<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H8F49FCDCFD0E4A30A07297DE9DFDF171" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 931 IH: Helping Effective Antibiotics Last Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-02-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 931</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150212">February 12, 2015</action-date>
			<action-desc><sponsor name-id="D000216">Ms. DeLauro</sponsor> (for herself, <cosponsor name-id="S000480">Ms. Slaughter</cosponsor>, and <cosponsor name-id="M001188">Ms. Meng</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To provide for approval of certain drugs and biological products indicated for use in a
			 well-defined population of patients in order to address increases in
			 bacterial resistance to drugs and biological products, and for other
			 purposes.</official-title>
	</form>
	<legis-body id="HE07FFEF5C953456F8A602C1BCA1AA63B" style="OLC">
 <section id="H9639CCEEBB654B0E8197FA775C67EB41" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Helping Effective Antibiotics Last Act of 2015</short-title></quote> or the <quote><short-title>HEAL Act</short-title></quote>.</text> </section><section id="HFACB5DEA8E4C4C2EA6A4B8D830A609ED"><enum>2.</enum><header>Approval of certain drugs for use in a well-defined population of patients</header> <subsection id="H43E357F01D0D4BCA960032C6AC912139"><enum>(a)</enum><header>Approval of Certain Antibacterial</header><text>Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block id="H4CDD0E6569DD4B45B0CD818CB495AA74" style="OLC">
					<subsection id="H50C9C47C17C24F2C956B3079668FB5FA"><enum>(x)</enum><header>Approval of certain antibacterial drugs for use in a well-Defined population of patients</header>
 <paragraph id="H0CAD96A952584A258CE12ECEE4091A8D"><enum>(1)</enum><header>Unmet medical need defined</header><text>In this subsection, the term <term>unmet medical need</term> means that the antibacterial drug involved—</text> <subparagraph id="HE71982EE87B64F658F4C99A9450D3DCF"><enum>(A)</enum><text>has improved efficacy, as demonstrated in adequate, well-controlled studies in humans, for specific diseases or conditions, where current therapies have been shown to be less effective;</text>
 </subparagraph><subparagraph id="H88AA9C62DBCC4F9480238CAC236BCD8E"><enum>(B)</enum><text>has clinically meaningful decreased harms, demonstrated in adequate, well-controlled studies in humans, for diseases or conditions, where current therapies have unacceptable adverse effects; or</text>
 </subparagraph><subparagraph id="H7DF0DE0A60C7451983B279D675B1050D"><enum>(C)</enum><text>has improved convenience, as demonstrated in adequate, well-controlled studies in humans, where improved convenience results in improved effectiveness or decreased harms.</text>
 </subparagraph></paragraph><paragraph id="H5F206017DF81421F85967655EC93EC1D"><enum>(2)</enum><header>Approval</header><text>Upon receipt of an application under subsection (b) for an antibacterial drug that is intended to treat a serious or life-threatening disease or condition, irrespective of whether the drug is intended to address an unmet medical need, the Secretary—</text>
 <subparagraph id="H0C48311F3D004DEA86FD553DDD6A789F"><enum>(A)</enum><text>may approve the drug under subsection (c) only for treating a well-defined population of patients, and based upon the results of clinical trials inclusive of human subjects representative of such well-defined population;</text>
 </subparagraph><subparagraph id="H4C5F7389D6294A3CA23543F3E9FE4CA9"><enum>(B)</enum><text display-inline="yes-display-inline">in determining whether to grant such approval, shall rely on superior outcomes over available therapies based on direct measures of patient benefits, as demonstrated in adequate, well-controlled studies in the well-defined patient population, such as—</text>
 <clause id="H09920CDE17034D4D8F74F1ABB97C9169"><enum>(i)</enum><text>decreased mortality;</text> </clause><clause id="H0EBFD662A0654F8383835F0D4F16B233"><enum>(ii)</enum><text>irreversible morbidity; or</text>
 </clause><clause id="H893B9600012544E987C3A388EC6EE61B"><enum>(iii)</enum><text>validated surrogate endpoints that reflect mortality or irreversible morbidity; and</text> </clause></subparagraph><subparagraph id="HF09A47B52BAE414C8EE2C7FA766DB857"><enum>(C)</enum><text>shall require the labeling of drugs approved pursuant to this subsection to prominently include in the prescribing information required by section 201.57 of title 21, Code of Federal Regulations (or any successor regulation)—</text>
 <clause id="H039A134F695A4AE4ABCD95E00B05ED42"><enum>(i)</enum><text display-inline="yes-display-inline">the population of patients with respect to which the added benefit over available therapies is expected as studied in adequate, well-controlled studies that form the basis for approval; and</text>
 </clause><clause id="HCEB485922603443393029C0A6D443222"><enum>(ii)</enum><text>the method for identifying members of that population.</text> </clause></subparagraph></paragraph><paragraph id="HA52C5BF3E2A6410EA6849F4FB37CA898"><enum>(3)</enum><header>Risk evaluation and mitigation strategy</header><text>The Secretary—</text>
 <subparagraph id="HAD58CF6B12274F298293187393C9A9E8"><enum>(A)</enum><text>shall require a risk evaluation and mitigation strategy (REMS) under section 505–1 for each drug approved under this subsection; and</text>
 </subparagraph><subparagraph id="H046D8A6BCB3E417BA772BDF324ADADAE"><enum>(B)</enum><text>may include in any such strategy additional elements to assure the safe use of the drug under subsections (e) and (f) of section 505–1.</text>
 </subparagraph></paragraph><paragraph id="H75FA8A09784F41968D08C00CF5867846"><enum>(4)</enum><header>Rule of construction</header><text>Nothing in this subsection shall be construed to alter the standards of evidence under subsection (c) or (d) (including the substantial evidence standard in subsection (d)). Subsections (c) and (d) and such standards of evidence apply to the review and approval of drugs under this subsection, including whether a drug is safe and effective. Nothing in this subsection shall be construed to limit the authority of the Secretary to approve products pursuant to this Act and the Public Health Service Act as authorized prior to the date of enactment of this subsection.</text>
 </paragraph><paragraph id="H6709949DC2AC4675A43EEF2D5152C307"><enum>(5)</enum><header>Effective immediately</header><text>The Secretary shall have the authorities vested in the Secretary by this subsection beginning on the date of enactment of this subsection, irrespective of when and whether the Secretary promulgates final regulations to carry out this subsection.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HC84482E075724A0A95FE4A727CF17ABC"><enum>(b)</enum><header>Licensure of certain biological products</header><text>Section 351(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(j)</external-xref>) is amended—</text> <paragraph id="HE9AAFC071A1B420F9D2E5C0D546F4F99"><enum>(1)</enum><text>by striking <quote>(j)</quote> and inserting <quote>(j)(1)</quote>;</text>
 </paragraph><paragraph id="H0DE6A05BCE2145858EAB359EE5E782CD"><enum>(2)</enum><text>by inserting <quote>505(x),</quote> after <quote>505(p),</quote>; and</text> </paragraph><paragraph id="H62E99B4264944669B64DD0D33FC4CDF9"><enum>(3)</enum><text>by adding at the end the following:</text>
					<quoted-block id="H48797E6F10874E03A1417BA9CB0211E5" style="OLC">
 <paragraph id="HE1F93806442A4088A56AD267ADD097F9" indent="up1"><enum>(2)</enum><text>In applying section 505(x) of the Federal Food, Drug, and Cosmetic Act to the licensure of biological products under this section—</text>
 <subparagraph id="HE2A25F43364A4BB2A97D75CB45E7480D"><enum>(A)</enum><text>references to an antibacterial drug with added benefits over available therapies for a well-defined population that is intended to treat a serious or life-threatening disease or condition shall be construed to refer to biological products with added benefits over available therapies for a well-defined population intended to treat a bacterial infection associated with a serious or life-threatening disease; and</text>
 </subparagraph><subparagraph id="H9972BF3E9A944AAF9ADC847B1463534A"><enum>(B)</enum><text>references to an application submitted under section 505(b) of such Act and to approval of a drug under section 505(c) of such Act shall be construed to refer to an application submitted under subsection (a) of this section and to licensure of a biological product under such subsection (a), respectively.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H9BC64CC7B2244D4D9F1B1353C0F25257"><enum>(c)</enum><header>Monitoring</header><text>Title III of the Public Health Service Act is amended by inserting after section 317T (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-22">42 U.S.C. 247b–22</external-xref>) the following:</text>
				<quoted-block id="HDA3D3B01B85E44678D3B02B81F7422B7" style="OLC">
					<section id="H59D30645BDD44EC5AF43AB25C50A15E0"><enum>317U.</enum><header>Monitoring of Antibacterial Drug Use, Patient Outcomes, and Resistance</header>
 <subsection id="H8B48271A2A7040F09CBB4BD05A947C81"><enum>(a)</enum><header>Monitoring</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall use the National Healthcare Safety Network or another appropriate monitoring system to monitor—</text>
 <paragraph id="HC9A37E3931D840FB994C226D673F32A8"><enum>(1)</enum><text>changes in patient outcomes such as mortality and irreversible morbidity causally related to antibacterial resistance; and</text>
 </paragraph><paragraph id="H5610446016574731BF79C60C73FAD413"><enum>(2)</enum><text>changes in bacterial resistance to drugs in relation to patient outcomes.</text> </paragraph></subsection><subsection id="H2ACE005EC0344D498316FBFD6BABD591"><enum>(b)</enum><header>Public availability of data</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall make the data derived from monitoring under this section publicly available for the purposes of—</text>
 <paragraph id="H5D2E33F8BA6B4397B79A24CDAB113957"><enum>(1)</enum><text>improving the monitoring of important trends in patient outcomes in relation to antibacterial resistance; and</text>
 </paragraph><paragraph id="HD156D3EAA1FD4E3986E8FC2A1AC2043F"><enum>(2)</enum><text>ensuring appropriate stewardship of antibacterial drugs, including those receiving approval or licensure for a well-defined population pursuant to section 505(x) of the Federal Food, Drug, and Cosmetic Act.</text></paragraph></subsection></section><after-quoted-block>. </after-quoted-block></quoted-block>
			</subsection></section><section id="HDE48949516564C72BF49B2E736237C3C"><enum>3.</enum><header>Susceptibility test interpretive criteria for microbial organisms</header>
 <subsection id="H17BA043560A3414AAF08BB91785F52D5"><enum>(a)</enum><header>In general</header><text>Section 511 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360a">21 U.S.C. 360a</external-xref>) is amended to read as follows:</text>
				<quoted-block id="HB657C4391FE44CB3A695232A450D6E20" style="OLC">
					<section id="H3E0F6838B4F8418C81BD7054D8382D66"><enum>511.</enum><header>Susceptibility test interpretive criteria for microbial organisms</header>
 <subsection id="H26A2891D2ADB4FAFA0C40E3D3361CA5A"><enum>(a)</enum><header>In general</header><text>The Secretary shall—</text> <paragraph id="H9798FC12A008497D8900F028DF5C75CF"><enum>(1)</enum><text display-inline="yes-display-inline">identify upon approval or licensing of antibacterial drugs (including biological products intended to treat a bacterial infection and other types of antimicrobial drugs, as deemed appropriate by the Secretary), including qualified infectious disease products, susceptibility test interpretive criteria for such drugs based upon patient outcomes of mortality and morbidity from adequate and well-controlled studies and such other confirmatory evidence as the Secretary deems necessary; and</text>
 </paragraph><paragraph id="HEE60C22FE94C4AD388AE28A96A66B35A"><enum>(2)</enum><text display-inline="yes-display-inline">update, consistent with subsection (b), such criteria as needed based upon scientific evidence of changes in patient outcomes.</text>
							</paragraph></subsection><subsection id="H549652C5E964450A98BD5DC6780A0C41"><enum>(b)</enum><header>Responding to Changes in Patient Outcomes To Evaluate Susceptibility Test Interpretive Criteria</header>
 <paragraph id="H3EA5736FC9EC4764B00FFFD0515B6BBA"><enum>(1)</enum><header>In general</header><text>As needed based on evidence related to changes in patient outcomes, the Secretary shall—</text> <subparagraph id="HACEA01024C2F4E4FB3872CCD5DCB3177"><enum>(A)</enum><text>evaluate any new scientific studies on changes in patient outcomes in relation to susceptibility test interpretive criteria; and</text>
 </subparagraph><subparagraph id="H55310EA8E3CC4EB29697911F8815F0DD"><enum>(B)</enum><text>publish on the public Website of the Food and Drug Administration a notice—</text> <clause id="H2F79F6713B4743CE9CD16CE85F6DC459"><enum>(i)</enum><text>presenting suggested new or updated interpretive criteria; and</text>
 </clause><clause id="HFD74CC87344143409F2EFE00552D1628"><enum>(ii)</enum><text>if needed, hold a public advisory committee to discuss scientific evidence related to changes in interpretative criteria.</text>
 </clause></subparagraph></paragraph><paragraph id="HE67B3D57C4D94CCCB41DE0B7B36CB176"><enum>(2)</enum><header>Annual compilation of notices</header><text>Each year, the Secretary shall compile the notices published under paragraph (1)(B) noting any changes from prior notices and publish such compilation in the Federal Register.</text>
 </paragraph></subsection><subsection id="H2F1AB21D49E040BAAAA749A5CCF4D22B"><enum>(c)</enum><header>Definition</header><text>In this section, the term <term>susceptibility test interpretive criteria</term> means one or more specific values which characterize patient outcomes in relation to the degree to which bacteria or other microbes are more resistant to treatment as measured by patient outcomes.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H6C4394A80A914D36967A63859ACAFA09"><enum>(b)</enum><header>Conforming amendment</header><text>Section 1111 of the Food and Drug Administration Amendments Act of 2007 (42 U.S.C. 247d–5a; relating to identification of clinically susceptible concentrations of antimicrobials) is repealed.</text>
 </subsection><subsection id="H71646DB094DE40D999F89EED0B674089"><enum>(c)</enum><header>Report to congress</header><text>Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the progress made in implementing section 511 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360a">21 U.S.C. 360a</external-xref>), as amended by this section.</text>
			</subsection></section><section id="HEEBF721BC14940B9A30FE7735CEA2A34"><enum>4.</enum><header>Requiring demonstration of superior outcomes for qualified infectious disease products To receive
 an extended exclusivity period</header><text display-inline="no-display-inline">Section 505E(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f(g)</external-xref>) is amended by striking <quote>means an antibacterial or antifungal drug for human use intended to treat</quote> and inserting <quote>means an antibacterial or antifungal drug for human use that is demonstrated to produce superior outcomes over available therapies, based on direct measures of patient benefits in clinical trials, and that is intended to treat</quote>.</text>
 </section><section id="H7200ACB03D2F4A14BAAEFF823CF9C571"><enum>5.</enum><header>Guidance on target product profiles</header><text display-inline="no-display-inline">Not later than 18 months after the date of enactment of this Act, the Commissioner of Food and Drugs, in consultation with the Administrator of the Centers for Medicare &amp; Medicaid Services, the Director of the Indian Health Service, the Secretary of Defense, and the Secretary of Veterans Affairs, shall issue guidance on the development of target product profiles for novel antibacterial drugs focused on public health priorities.</text>
		</section></legis-body>
</bill>


